Espicom


The Pharmaceutical Market: Indonesia

Published 20 March 2014

  • 140 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Indonesia

Table of Contents

Executive Summary
6
SWOT Analysis
8
Indonesia Pharmaceutical And Healthcare Industry SWOT
8
Indonesia Political SWOT
9
Indonesia Economic SWOT
9
Indonesia Business Environment SWOT
10
Pharmaceutical Risk/Reward Ratings
11
Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q213
11
Rewards
12
Risks
13
Market Summary - Indonesia
14
Regulatory Regime
16
Pharmaceutical Advertising
18
Regional Harmonisation
19
Intellectual Property Issues
20
Halal Medicine Regulations
21
Compulsory Licensing
22
Counterfeit Drugs
22
Generic Drug Legislation
24
Labelling Requirements
24
Free Trade Agreements
25
Pricing Regime
26
Reimbursement Regime
28
Industry Trends And Developments
30
Epidemiology
30
Non-Communicable Diseases
31
Communicable Diseases
32
HIV/AIDS
33
Public Health Developments
35
Table: UN Millennium Development Goals For Indonesia
36
Healthcare System
36
Health Insurance
38
Healthcare System Reform
40
Medical Tourism
41
Research & Development
41
Clinical Trials
43
Herbal Medicines
44
Industry Forecast Scenario
45
Pharmaceutical Market Forecast
45
Table: Indonesia Pharmaceutical Sales, Historical Data and Forecasts
47
Healthcare Market Forecast
48
Table: Indonesia Healthcare Expenditure Trends, Historical Data and Forecasts
50
Table: Indonesia Government Healthcare Expenditure Trends, Historical Data and Forecasts
51
Table: Indonesia Private Healthcare Expenditure Trends, Historical Data and Forecasts
51
Key Growth Factors - Macroeconomic
52
Prescription Drug Market Forecast
55
Table: Indonesia Prescription Drug Market Indicators, Historical Data and Forecasts
56
Patented Drug Market Forecast
57
Table: Indonesia Patented Drug Market Indicators, Historical Data and Forecasts
58
Generic Drug Market Forecast
59
Table: Indonesia Generics Drug Market Indicators, Historical Data and Forecasts
60
OTC Medicine Market Forecast
62
Table: Indonesia Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
63
Table: OTC Medicine Sales By Category, 2006-2010
64
Pharmaceutical Trade Forecast
65
Table: Indonesia Pharmaceutical Trade Data And Forecasts (US$mn)
67
Table: Indonesia Pharmaceutical Trade Data And Forecasts (IDRmn)
67
Other Healthcare Data
68
Key Risks To BMI's Forecast Scenario
69
Competitive Landscape
70
Pharmaceutical Industry
70
Table: Pharmaceutical Manufacturers By Region, 2000-2010
70
Table: Selected List Of Pharmaceutical Business Areas With Restricted Conditions
71
Table: Top-10 Pharmaceutical Companies According To Market Capitalisation
72
Domestic Industry
72
Foreign Industry
74
Table: Members Of The International Pharmaceutical Manufacturers Group (IPMG)
74
Recent Pharmaceutical Sector Developments
75
Pharmaceutical Wholesaling
75
Pharmaceutical Retail
76
Company Profiles
79
Domestic Companies
79
Soho Group
79
Darya-Varia Group
81
PT Kalbe Farma
83
PT Bio Farma
86
Kimia Farma
88
Combiphar PT
91
Multinational Companies
92
Sanofi
92
Pfizer
94
Novartis
96
GlaxoSmithKline
98
Merck & Co
100
Bayer
102
Merck Group
104
Demographic Outlook
106
Table: Population By Age Group, 1990-2020 ('000)
107
Table: Population By Age Group, 1990-2020 (% of total)
108
Table: Key Population Ratios, 1990-2020
109
Table: Rural/Urban Population Split, 1990-2020
109
BMI Methodology
110
How We Generate Our Pharmaceutical Industry Forecasts
110
Pharmaceutical Risk/Reward Ratings Methodology
111
Ratings Overview
111
Table: Pharmaceutical Business Environment Indicators
112
Weighting
113
Table: Weighting Of Components
113
Sources
113
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDONESIA

Indonesia's new goal to establish universal healthcare coverage by 2019 rather than 2014 is more feasible given that the programme will be rolled out in phases. We continue to see universal healthcare coverage as a key theme in Asia, although poor governance in several countries across the region will delayitsimplementation. Despite this, pharmaceutical firms will continue to enjoy strong growth in the region due to the expanding, increasingly ageing and affluent population, which will boost volume demand for pharmaceuticals as well as medical services across the board.

HeadlineExpenditure Projections

Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,657bn (US$6.25bn) in 2012; +10.6% growth in local currency terms and +3.5% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Healthcare: IDR195,355bn (US$22.26bn) in 2011 to IDR223,454bn (US$23.82bn) in 2012; +14.4% growth in local currency terms and +7.0% in US dollar terms. Local currency forecastunchanged from previous quarter.

Medicaldevices: IDR5,721bn (US$652mn) in 2011 to IDR6,282bn (US$670mn) in 2012; +9.8% growth in local currency terms and +2.7% in US dollar terms. Local currency forecastbroadlyunchanged from previous quarter.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%